Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 21;64(5):e01955-19.
doi: 10.1128/AAC.01955-19. Print 2020 Apr 21.

Activity of Cefiderocol and Comparators against Isolates from Cancer Patients

Kenneth V I Rolston  1 , Baghat Gerges  2 , Samuel Shelburne  2 , Samuel L Aitken  3 , Issam Raad  2 , Randall A Prince  2
Affiliations

Activity of Cefiderocol and Comparators against Isolates from Cancer Patients

Kenneth V I Rolston et al. Antimicrob Agents Chemother. .

Abstract

Cefiderocol inhibited 97.5% of 478 Gram-negative isolates from cancer patients at ≤4 mg/liter. It had potent activity against extended-spectrum β-lactamase-positive Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae (CRE), and nonfermenting Gram-negative bacilli, including Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Acinetobacter species isolates. Amikacin, ceftazidime-avibactam, and meropenem had appreciable activity against non-CRE Enterobacteriaceae No comparators were active against multidrug-resistant P. aeruginosa isolates. Only trimethoprim-sulfamethoxazole had appreciable activity against S. maltophilia isolates. Overall, cefiderocol was associated with the lowest level of resistance.

Keywords: Gram-negative isolates; Pseudomonas aeruginosa; Stenotrophomonas maltophilia; cefiderocol.

PubMed Disclaimer

References

    1. Montassier E, Batard E, Gastinne T, Potel G, de la Cochetière MF. 2013. Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance. Eur J Clin Microbiol Infect Dis 32:841–850. doi: 10.1007/s10096-013-1819-7. - DOI - PubMed
    1. Kenneth VI, Rolston A, Freifeld A, Zimmer J, Baddley ZE, Boghdadly E, Maziarz J, Montoya S, Shoham L, Strasfeld J, Young Y, Zhang JM. 2018. Bloodstream infection survey in high-risk oncology patients (BISHOP) with fever and neutropenia (FN): microbiology data, abstr P0673. ECCMID 2018, Madrid, Spain.
    1. Rapoport B, Klastersky J, Raftopoulos H, Freifeld A, Aoun M, Zinner SH, Rolston KVI. 2016. The emerging problem of bacterial resistance in cancer patients; proceedings of a workshop held by MASCC “Neutropenia, Infection and Myelosuppression” Study Group during the MASCC annual meeting held in Berlin on 27–29 June 2013. Support Care Cancer 24:2819–2826. doi: 10.1007/s00520-016-3183-5. - DOI - PubMed
    1. Patel G, Bonomo RA. 2013. Stormy waters ahead: global emergence of carbapenemases. Front Microbiol 4:48. doi: 10.3389/fmicb.2013.00048. - DOI - PMC - PubMed
    1. Kohira N, West J, Ito A, Ito-Horiyama T, Nakamura R, Sato T, Rittenhouse S, Tsuji M, Yamano Y. 2016. In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae clinical isolates, including carbapenem-resistant strains. Antimicrob Agents Chemother 60:729–734. doi: 10.1128/AAC.01695-15. - DOI - PMC - PubMed

Publication types

MeSH terms